文献速递脊柱外科骨肿瘤

脊柱与骨盆软骨肉瘤癌症特异性死亡的竞争风险预后模型

A Competing Risk-based Prognostic Model to Predict Cancer-specific Death of Patients with Spinal and Pelvic Chondrosarcoma.
PubMed 文献 · Spine (Phila Pa 1976) · 2021-01-01

本研究基于SEER数据库623例脊柱或骨盆软骨肉瘤患者,分为训练队列与验证队列,构建并验证了考虑非CSD为竞争风险的竞争风险预后模型及列线图,用于预测3年和5年癌症特异性死亡(CSD)概率。模型区分度、校准图和决策曲线分析显示列线图预测性能良好、适合临床使用。

要点

  • 年龄较大、高级别、区域侵犯、远处转移与CSD风险升高相关。
  • 根治性切除与CSD风险降低相关(SHR 0.38)。
  • 列线图预测3年和5年CSD性能良好,适合临床使用。

核心结论

  • 基于竞争风险模型开发的列线图可预测脊柱与骨盆软骨肉瘤患者的CSD概率,性能良好且适合临床使用。

研究设计与样本

  • 回顾性分析,从SEER数据库识别623例脊柱或骨盆软骨肉瘤患者,分为训练队列和验证队列,开发并验证预测3年和5年CSD概率的竞争风险预后模型。

主要发现

  • 年龄较大SHR 1.02(95%CI 1.01∼1.03,P=0.013)、高级别SHR 2.68(95%CI 1.80∼3.99,P<0.001)、区域侵犯SHR 1.66(95%CI 1.06∼2.58,P=0.026)、远处转移SHR 5.18(95%CI 3.11∼8.62,P<0.001)与CSD发生显著相关。
  • 根治性切除SHR 0.38(95%CI 0.24∼0.60,P<0.001)与CSD发生显著相关。
  • C-index、校准图和决策曲线分析提示列线图预测CSD性能良好并适合临床使用。

关键数值与推荐

  • 模型预测目标为脊柱或骨盆软骨肉瘤患者3年和5年CSD概率,非CSD作为竞争风险。
  • 预测因子包括年龄、级别、区域侵犯、远处转移和根治性切除。
  • 证据等级为4级。

临床怎么用

  • 可依据年龄、肿瘤级别、区域侵犯、远处转移及是否根治性切除评估脊柱与骨盆软骨肉瘤患者3年和5年CSD概率,辅助临床决策。

局限性

  • 本研究为回顾性分析,证据等级为4级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Retrospective analysis. OBJECTIVE: The aim of this study was to develop and validate a competing-risk-based prognostic model and a nomogram for predicting the three- and five-year probability of cancer-specific death (CSD) in patients with spinal and pelvic chondrosarcoma. SUMMARY OF BACKGROUND DATA: The issue of competing risk has rarely been addressed and discussed in survival analysis of bone sarcoma. In addition, the Fine and Gray model, a more accurate method for survival analysis in the context of competing risk, has also been less reported in prognostic study of chondrosarcoma. METHODS: A total of 623 patients with spinal or pelvic chondrosarcoma were identified from the SEER database and were divided into a training and a validation cohort. These two cohorts were used to develop and validate a prognostic model to predict the 3- and 5-year probability of CSD, considering non-CSD as competing risk. The C-index, calibration plot, and decision curve analysis were used to assess the predictive performance and clinical utility of the model. RESULTS: Older age (subdistribution hazards ratio [SHR]: 1.02, 95% confidence interval [CI]: 1.01∼1.03; P = 0.013), high grade (SHR: 2.68, 95% CI: 1.80∼3.99; P < 0.001), regional involvement (SHR: 1.66, 95% CI: 1.06∼2.58; P = 0.026), distant metastasis (SHR: 5.18, 95% CI: 3.11∼8.62; P < 0.001) and radical resection (SHR: 0.38, 95% CI: 0.24∼0.60; P < 0.001) were significantly associated with the incidence of CSD. These factors were used to build a competing-risk-based model and a nomogram to predict CSD. The C-index, calibration plot, and decision curve analysis indicated that the nomogram performs well in predicting CSD and is suitable for clinical use. CONCLUSION: A competing-risk based prognostic model is developed to predict the probability of CSD of patients with spinal and pelvic chondrosarcoma. This nomogram performs well and is suitable for clinical use.Level of Evidence: 4.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Dong Y, Xie L, Kang H, et al. A Competing Risk-based Prognostic Model to Predict Cancer-specific Death of Patients with Spinal and Pelvic Chondrosarcoma. Spine (Phila Pa 1976). 2021. PMID: 34714793. doi:10.1097/BRS.0000000000004073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。